title: Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments.
abstract: Hyperkinetic Jak2 tyrosine kinase signaling has been implicated in several human diseases including leukemia, lymphoma, myeloma, and the myeloproliferative neoplasms. Using structure-based virtual screening, we previously identified a novel Jak2 inhibitor named G6. We showed that G6 specifically inhibits Jak2 kinase activity and suppresses Jak2-mediated cellular proliferation. To elucidate the molecular and biochemical mechanisms by which G6 inhibits Jak2-mediated cellular proliferation, we treated Jak2-V617F expressing human erythroleukemia (HEL) cells for 12 h with either vehicle control or 25 μM of the drug and compared protein expression profiles using two-dimensional gel electrophoresis. One differentially expressed protein identified by electrospray mass spectroscopy was the intermediate filament protein, vimentin. It was present in DMSO treated cells but absent in G6 treated cells. HEL cells treated with G6 showed both time- and dose-dependent cleavage of vimentin as well as a marked reorganization of vimentin intermediate filaments within intact cells. In a mouse model of Jak2-V617F mediated human erythroleukemia, G6 also decreased the levels of vimentin protein, in vivo. The G6-induced cleavage of vimentin was found to be Jak2-dependent and calpain-mediated. Furthermore, we found that intracellular calcium mobilization is essential and sufficient for the cleavage of vimentin. Finally, we show that the cleavage of vimentin intermediate filaments, per se, is sufficient to reduce HEL cell viability. Collectively, these results suggest that G6-induced inhibition of Jak2-mediated pathogenic cell growth is concomitant with the disruption of intracellular vimentin filaments. As such, this work describes a novel pathway for the targeting of Jak2-mediated pathological cell growth.
authors.affiliation: Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida 32610, United States.
authors.forename: Anurima
authors.initials: A
authors.lastname: Majumder
authors.forename: Annet
authors.initials: A
authors.lastname: Kirabo
authors.forename: Kanchana
authors.initials: K
authors.lastname: Karrupiah
authors.forename: Shigeharu
authors.initials: S
authors.lastname: Tsuda
authors.forename: Jennifer
authors.initials: J
authors.lastname: Caldwell-Busby
authors.forename: Arturo J
authors.initials: AJ
authors.lastname: Cardounel
authors.forename: György M
authors.initials: GM
authors.lastname: Keseru
authors.forename: Peter P
authors.initials: PP
authors.lastname: Sayeski
mesh_terms: D000818:Animals; D002154:Calpain / Q000378:metabolism; D016923:Cell Death; D045744:Cell Line, Tumor; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004915:Leukemia, Erythroblastic, Acute / Q000378:metabolism; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D021241:Spectrometry, Mass, Electrospray Ionization; D013267:Stilbenes / Q000494:pharmacology*; D014746:Vimentin / Q000737:chemistry / Q000378:metabolism*
chemical_list: D047428:Protein Kinase Inhibitors; D013267:Stilbenes; D014746:Vimentin; D053614:Janus Kinase 2; D002154:Calpain